# Table of Contents

## Highlights of This Issue 4731

### SPECIAL FEATURES

#### CCR Translations

4733 Prostate Cancer SubtyPINg BiomarkKers and Outcome: Is Clarity EmerGing?
Steven C. Smith and Scott A. Tomlins
See related article, p. 4904

4737 Twisting and Ironing: Doxorubicin Cardiotoxicity by Mitochondrial DNA Damage
Karin C. Nitiss and John L. Nitiss
See related article, p. 4873

### Molecular Pathways

4740 Molecular Pathways: Targeting RAC–p21-Activated Serine–Threonine Kinase Signaling in RAS-Driven Cancers
Nicole M. Baker, Hoi Yee Chow, Jonathan Chernoff, and Channing J. Der

### CANCER THERAPY: CLINICAL

4747 Phase I Dose-Escalation Study of MEDI-573, a Bispecific, Antiligand Monoclonal Antibody against IGF1 and IGFII, in Patients with Advanced Solid Tumors
Paul Haluska, Michael Meneece, Elizabeth R. Pilmack, Jonathan Rosenberg, Donald Northfelt, Theresa LaVallee, Li Shi, Xiang-Qing Yu, Patricia Burke, Jaiqi Huang, Jaye Viner, Jennifer McDevitt, and Patricia LoRusso

4758 Is the “3+3” Dose-Escalation Phase I Clinical Trial Design Suitable for Therapeutic Cancer Vaccine Development? A Recommendation for Alternative Design
Osama E. Rahma, Emily Gammoh, Richard M. Simon, and Samir N. Khleif

4768 The Role of Age on Dose-Limiting Toxicities in Phase I Dose-Escalation Trials

4776 Phase I Study of RGB-286638, A Novel, Multitargeted Cyclin-Dependent Kinase Inhibitor in Patients with Solid Tumors
Diane A.J. van der Biezen, Herman Burger, Peter de Bruijn, Cor H.J. Lamers, Nicole Naus, Hannes Loferer, Erik A.C. Wiemer, Ron H.J. Mathijssen, and Maja J.A. de Jonge

#### PERSONALIZED MEDICINE AND IMAGING

4784 A Three-microRNA Signature Predicts Responses to Platinum-Based Doublet Chemotherapy in Patients with Lung Adenocarcinoma
Motonobu Saito, Kouya Shiraishi, Kenji Matsumoto, Aaron J. Schetter, Hiroko Ogata-Kawata, Naoto Tsuchiya, Hideo Kunitoh, Hiroshi Nokihara, Shun-ichi Watanabe, Koji Taura, Kensuke Kumamoto, Seiichi Takenoshita, Jun Yokota, Curtis C. Harris, and Takashi Kohn

4794 Clinical Significance of EpCAM mRNA-Positive Circulating Tumor Cells in Hepatocellular Carcinoma by an Optimized Negative Enrichment and qRT-PCR-Based Platform
Wei Guo, Xin-Rong Yang, Yun-Fan Sun, Min-Na Shen, Xiao-Lu Ma, Jing Wu, Chun-Yan Zhang, Yan Zhou, Yang Xu, Bo Hu, Xin Zhang, Jian Zhou, and Jia Fan

4806 Monitoring Reversal of MET-Mediated Resistance to EGFR Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer Using 3'-Deoxy-3'-Fluorothymidine Positron Emission Tomography
Francesca Iommelli, Viviana De Rosa, Sara Gargiulo, Mariorosaria Panico, Marcello Monti, Adelaide Greco, Matteo Gramanzini, Giovanni Ortesco, Rosa Fonti, Arturo Brunetti, and Silvana Del Vecchio

4816 Functional Ex Vivo Assay to Select Homologous Recombination–Deficient Breast Tumors for PARP Inhibitor Treatment

---

Note: The table is derived from the Clinical Cancer Research Table of Contents and includes highlights, special features, and clinical cancer therapy studies. The page numbers and authors are listed for each section.
CANCER THERAPY: PRECLINICAL

4849 PI3K/mTOR Inhibition Markedly Potentiates HDAC Inhibitor Activity in NHL Cells through BIM- and MCL-1–Dependent Mechanisms In Vitro and In Vivo
Mohamed Rahmani, Mandy Mayo Aust, Elisa C. Benson, LaShanale Wallace, Jonathan Friedberg, and Steven Grant

4861 On-Target Effect of FK866, a Nicotinamide Phosphoribosyl Transferase Inhibitor, by Apoptosis-Mediated Death in Chronic Lymphocytic Leukemia Cells
Iris Gehrke, Eric D.J. Bouchard, Sara Beiggi, Armando G. Poepppl, James B. Johnston, Spencer B. Gibson, and Versha Banerji

BIOLOGY OF HUMAN TUMORS

4894 Novel MSH6 Mutations in Treatment-Naïve Glioblastoma and Anaplastic Oligodendroglioma Contribute to Temozolomide Resistance Independently of MGMT Promoter Methylation

4904 SPINK1 Protein Expression and Prostate Cancer Progression
Richard Flavin, Andreas Pettersson, Whitney K. Hendrickson, Michelangelo Fiorentino, Stephen Finn, Lauren Kunz, Gregory L. Judson, Rosina Lis, Dyane Bailey, Christopher Fiore, Elizabeth Nuttall, Neil E. Martin, Edward Stack, Kathryn L. Penney, Jennifer R. Rider, Jennifer Sinnott, Christopher Sweeney, Howard D. Sesso, Katja Fall, Edward Giovannucci, Philip Kantoff, Meer Stamper, Massimo Loda, and Lorelei A. Mucci
See related commentary, p. 4733

4912 Genomic and Transcriptional Alterations in Lung Adenocarcinoma in Relation to Smoking History
Anna Karlsson, Markus Ringné, Martin Lauss, Johan Botling, Patrick Micke, Maria Planck, and Johan Staaf

4925 Evidence for Molecular Differences in Prostate Cancer between African American and Caucasian Men
Francesca Khani, Juan Miguel Mosquera, Kyung Park, Mirjam Blattner, Catherine O’Reilly, Theresa Y. MacDonald, Zhengming Chen, Abhishek Srivastava, Ashutosh K. Tewari, Christopher E. Barbieri, Mark A. Rubin, and Brian D. Robinson

4935 Concurrent Alterations in TERT, KDM6A, and the BRCA Pathway in Bladder Cancer
Michael L. Nickerson, Garrett M. Dancik, Kate M. Im, Michael G. Edwards, Sevilay Turan, Joseph Brown, Christina Ruiz-Rodriguez, Charles Owens, James C. Costello, Guangvu Guo, Shirley X. Tsang, Yingrui Li, Quan Zhou, Zhiming Cai, Lee E. Moore, M. Scott Lucia, Michael Dean, and Dan Theodorescu

4949 T-box Transcription Factor Brachyury Is Associated with Prostate Cancer Progression and Aggressiveness
Filipe Pinto, Neila Pertega-Gomes, Márcia S. Pereira, José R. Vizcaíno, Pedro Monteiro, Rui M. Henrique, Fátima Baltazar, Raquel P. Andrade, and Rui M. Reis
LETTERS TO THE EDITOR

4971  Androstenedione Is the Preferred Androgen Source in Hormone Refractory Prostate Cancer—Letter
Nima Sharifi and Richard J. Auchus

CORRECTION

4974  Correction: Prevalence and Clinical Implications of Epstein–Barr Virus Infection in De Novo Diffuse Large B-Cell Lymphoma in Western Countries

ABOUT THE COVER

The cover shows results from FISH analysis of prostate cancer cells with ERG rearrangement (top; loss of one green signal indicating translocation through deletion) and hemizygous PTEN deletion (bottom; loss of one red signal with preservation of green centromeric signals). For details, see the article by Khani and colleagues on page 4925 of this issue.